A model for harmonizing flow cytometry in clinical trials.


Complexities in sample handling, instrument setup and data analysis are barriers to the effective use of flow cytometry to monitor immunological parameters in clinical trials. The novel use of a central laboratory may help mitigate these issues.





Published Version (Please cite this version)


Publication Info

Maecker, Holden T, J Philip McCoy, undefined FOCIS Human Immunophenotyping Consortium, Michael Amos, John Elliott, Adolfas Gaigalas, Lili Wang, Richard Aranda, et al. (2010). A model for harmonizing flow cytometry in clinical trials. Nat Immunol, 11(11). pp. 975–978. 10.1038/ni1110-975 Retrieved from https://hdl.handle.net/10161/14743.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.